Completed PHASE3 INTERVENTIONAL 2-arm NCT01031992

Tranexamic Acid and Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) (TAHHT)

Efficacy of Tranexamic Acid Taken Orally in Patients With Hereditary Hemorrhagic Telangiectasia

Sponsor: Baxter Healthcare Corporation

Conditions Hereditary Hemorrhagic Telangiectasia

Interventions First placebo, than Tranexamic acid. Tranexamic acid first, than placebo

Updated 5 times since 2017 Last updated: Dec 12, 2009 Started: Mar 31, 2002 Primary completion: Aug 31, 2002 Completion: Oct 31, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Hereditary Hemorrhagic Telangiectasia, this trial is completed. The trial is conducted by Baxter Healthcare Corporation and has accumulated 5 data snapshots since 2002. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Mar 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Baxter Healthcare Corporation
Pharmacia GmbH, Erlangen, Germany
University Hospital, Saarland

Data source: University Hospital, Saarland

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Homburg, Germany